The FDA has approved tocilizumab-aazg (Tyenne), the first tocilizumab biosimilar, for treating rheumatic diseases, as well as the new drug application for CB-101, a chimeric antigen receptor T cell therapy, for treating lupus nephritis and extra-renal lupus.
![](https://www.the-rheumatologist.org/wp-content/uploads/2024/03/needle-syringe-150x150.png)